Product class:
|
Authorized package
|
Medicinal product class:
|
For human use
|
Package code:
|
1203433
|
Name of medicinal product:
|
AZILECT
|
Active substances:
|
|
ATC code:
|
N04BD02
|
Dosage form:
|
tablet
|
Route of administration:
|
oral use
|
Strengh:
|
1mg
|
Amount in package:
|
30TK
|
Legal status for supply*:
|
Subject to medicinal prescription
|
Class of active substance:
|
|
Additional information:
|
|
Indication:
|
AZILECT is indicated for the treatment of idiopathic Parkinsons disease (PD) as monotherapy
(without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
|
Safety features:
|
Yes
|
Summary of product characteristics (SPC):
|
|
Package information leaflet (PIL):
|
EST
|
Labelling:
|
|
Last imported to Estonia:
|
Never imported to Estonia
|
Marketing authorization holder:
|
Teva B.V.
|
Marketing authorization number:
|
EU/1/04/304
|
Marketing authorization issued on:
|
February 21, 2005
|
Marketing authorization expires on:
|
Unlimited
|
Marketing authorization procedure type:
|
Centralised
|
Reference price:
|
|
Under reference price:
|
|
Reference price of daily dose:
|
|
Entry/Changing date:
March 16, 2016
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere